William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on OCUL stock, giving a Buy rating on October 30.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lachlan Hanbury Brown has given his Buy rating due to a combination of factors, primarily focusing on Ocular Therapeutix’s strong execution and promising future prospects. The company has demonstrated exceptional retention and adherence to protocol in its SOL-1 trial, with impressive patient retention rates and adherence to planned rescue injection schedules. This indicates a well-managed clinical trial process, which is crucial for the success of their upcoming top-line data release in 2026.
Additionally, the successful randomization of 555 patients in the SOL-R trial and the imminent initiation of the HEALIOS program for diabetic retinopathy further bolster the company’s growth potential. The recent equity financing of approximately $445 million provides Ocular with the necessary resources to support these initiatives, including manufacturing investments. The company’s financial performance, evidenced by Dextenza’s net revenues exceeding expectations, despite a challenging reimbursement environment, also supports the positive outlook. These elements collectively contribute to the Buy rating, reflecting confidence in Ocular’s strategic direction and execution capabilities.
In another report released on October 30, TD Cowen also maintained a Buy rating on the stock with a $20.00 price target.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of OCUL in relation to earlier this year.